| News

DayOne Catalyst Project: Oonida

04.02.2019

One of the pillars of BaselArea.swiss’ DayOne (www.DayOne.swiss) strategy is to drive Catalyst projects – collaborative approaches to bottleneck issues in Healthcare innovation. These are “wicked problems” that can only be solved collaboratively. Therefore, Catalyst Projects focus on challenges to which it is difficult to find solutions within the current industry structures.

DayOne Catalyst project workshop (img: Frank Kumli)
DayOne Catalyst project workshop (img: Frank Kumli)

The access to healthcare data is one of the best-known bottleneck issues in healthcare innovation and is being addressed by Oonida. The Basel based not-for-profit company is building a citizen centric platform where health data can be shared between patients and all relevant healthcare stakeholders. As a neutral steward OoNiDa aims to improve the efficiency within the ecosystem and overall population health by encouraging free flow of information in the health ecosystem so services and care can be delivered more efficiently and innovation can be stimulated.

New insights and connections

On behalf of OoNiDa DayOne brought together 15 volunteering healthcare innovators across industry and disciplines from the Basel ecosystem. During a full-day workshop at the DayOne Innovation Lab in the Technologiepark Basel, the OoNiDa management was able to validate and refine their business model and to come up with a minimal viable product that could be launched and tested in the local market.

“It is a unique experience for a startup in the very early stage like ours, to get access to some of the brightest minds in the Basel Healthcare Innovation Ecosystem. Not only did we gain new insights but could also make most valuable connections to future partners and customers of our platform”, stated Andy Bushell, Founder and CEO of OoNiDa.

Learn more…

… about the workshop with Oonida and about our Catalyst projects www.dayone.ch/projects.

If you or your organization would like to launch a Catalyst project, please contact frank.kumli@baselarea.swiss

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

VectivBio secures investments totaling 110 million dollars
Basel Area Business & Innovation, Innovation, Invest

VectivBio secures investments totaling 110 million dollars

The Basel-based biotechnology firm VectivBio has received a capital injection of 110 million US dollars from both new and existing...

Read More
Polyphor receives up to 18 million dollars for development of antibiotics
Basel Area Business & Innovation, Innovation, Invest

Polyphor receives up to 18 million dollars for development of antibiotics

The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor...

Read More
What makes Switzerland’s economy resilient in face of COVID pandemic
Basel Area Business & Innovation, Invest

What makes Switzerland’s economy resilient in face of COVID pandemic

The COVID-19 pandemic has hit economies worldwide – and we have not yet overcome it. However, Switzerland is among the...

Read More
DayOne Accelerator applications open
Basel Area Business & Innovation, Innovation

DayOne Accelerator applications open

We are excited to announce the opening of the call for the DayOne Accelerator, now in its 3rd year!

Read More
Matériaux Sabag printing concrete elements
Basel Area Business & Innovation, Innovation, Invest

Matériaux Sabag printing concrete elements

The Jura-based company Matériaux Sabag is now using a 3D printing solution to produce its concrete elements. This approach allows...

Read More
Six companies win the i4Challenge
Basel Area Business & Innovation, Innovation

Six companies win the i4Challenge

The i4Challenge expert jury has selected six winners from 18 finalists. The Industry 4.0 solutions range from 3D printing, IoT,...

Read More
Monte Rosa Therapeutics banks 96 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Monte Rosa Therapeutics banks 96 million US dollars

The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful...

Read More
Roche launches new coronavirus antibody test
Basel Area Business & Innovation, Innovation, Invest

Roche launches new coronavirus antibody test

Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development...

Read More
Investors see great potential in Polyneuron
Basel Area Business & Innovation, Innovation, Invest

Investors see great potential in Polyneuron

The Basel-based company Polyneuron Pharmaceuticals extended its Series A funding round and has now raised a total of 36.5 million...

Read More
Lonza set to manufacture coronavirus drug for Humanigen
Basel Area Business & Innovation, Innovation, Invest

Lonza set to manufacture coronavirus drug for Humanigen

The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...

Read More
1 2 3 21

Do you have a question? We'd like to hear from you.